CA2768340A1 - Copolymeres destines a la suppression de maladies auto-immunes, et methodes d'utilisation - Google Patents

Copolymeres destines a la suppression de maladies auto-immunes, et methodes d'utilisation Download PDF

Info

Publication number: CA2768340A1
Authority: CA; Canada
Prior art keywords: copolymer; amino acid; molar ratio; copolymers; lysine
Prior art date: 2001-10-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA2768340A

Other languages

English (en)

Other versions

CA2768340C (fr

Inventor

Jack L. Strominger

Masha Fridkis-Hareli

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Harvard University

Original Assignee

Harvard University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-03

Filing date

2002-10-03

Publication date

2003-04-10

2002-10-03 Application filed by Harvard University filed Critical Harvard University

2002-10-03 Priority claimed from CA2614171A external-priority patent/CA2614171C/fr

2003-04-10 Publication of CA2768340A1 publication Critical patent/CA2768340A1/fr

2015-06-30 Application granted granted Critical

2015-06-30 Publication of CA2768340C publication Critical patent/CA2768340C/fr

2022-10-03 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

229920001577 copolymer Polymers 0.000 title claims description 207
238000000034 method Methods 0.000 title claims description 40
208000023275 Autoimmune disease Diseases 0.000 title claims description 36
230000001629 suppression Effects 0.000 title description 20
235000001014 amino acid Nutrition 0.000 claims description 114
150000001413 amino acids Chemical class 0.000 claims description 72
108090000765 processed proteins & peptides Proteins 0.000 claims description 59
239000000203 mixture Substances 0.000 claims description 44
230000027455 binding Effects 0.000 claims description 39
201000006417 multiple sclerosis Diseases 0.000 claims description 39
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 31
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 29
239000004472 Lysine Substances 0.000 claims description 29
235000004279 alanine Nutrition 0.000 claims description 29
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 24
239000003814 drug Substances 0.000 claims description 24
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 23
239000004474 valine Substances 0.000 claims description 23
229940124597 therapeutic agent Drugs 0.000 claims description 21
102000004127 Cytokines Human genes 0.000 claims description 18
108090000695 Cytokines Proteins 0.000 claims description 18
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 14
125000000539 amino acid group Chemical group 0.000 claims description 13
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 13
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 10
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 10
239000002981 blocking agent Substances 0.000 claims description 10
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 10
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 8
230000005867 T cell response Effects 0.000 claims description 8
239000002532 enzyme inhibitor Substances 0.000 claims description 8
229940125532 enzyme inhibitor Drugs 0.000 claims description 8
230000002401 inhibitory effect Effects 0.000 claims description 8
206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
208000016192 Demyelinating disease Diseases 0.000 claims description 7
230000000599 auto-anti-genic effect Effects 0.000 claims description 7
239000003242 anti bacterial agent Substances 0.000 claims description 6
235000013922 glutamic acid Nutrition 0.000 claims description 6
239000004220 glutamic acid Substances 0.000 claims description 6
102000003814 Interleukin-10 Human genes 0.000 claims description 5
108090000174 Interleukin-10 Proteins 0.000 claims description 5
102000004388 Interleukin-4 Human genes 0.000 claims description 5
108090000978 Interleukin-4 Proteins 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
229940076144 interleukin-10 Drugs 0.000 claims description 5
229940028885 interleukin-4 Drugs 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
150000003431 steroids Chemical class 0.000 claims description 5
230000000844 anti-bacterial effect Effects 0.000 claims description 4
230000000340 anti-metabolite Effects 0.000 claims description 4
229940100197 antimetabolite Drugs 0.000 claims description 4
239000002256 antimetabolite Substances 0.000 claims description 4
108010057085 cytokine receptors Proteins 0.000 claims description 4
102000003675 cytokine receptors Human genes 0.000 claims description 4
208000003532 hypothyroidism Diseases 0.000 claims description 4
230000002989 hypothyroidism Effects 0.000 claims description 4
238000003746 solid phase reaction Methods 0.000 claims description 4
229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims description 3
208000003807 Graves Disease Diseases 0.000 claims description 3
208000015023 Graves' disease Diseases 0.000 claims description 3
208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
208000028622 Immune thrombocytopenia Diseases 0.000 claims description 3
206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
206010028665 Myxoedema Diseases 0.000 claims description 3
201000011152 Pemphigus Diseases 0.000 claims description 3
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
206010046851 Uveitis Diseases 0.000 claims description 3
239000003443 antiviral agent Substances 0.000 claims description 3
208000006424 autoimmune oophoritis Diseases 0.000 claims description 3
230000001684 chronic effect Effects 0.000 claims description 3
206010009887 colitis Diseases 0.000 claims description 3
230000004048 modification Effects 0.000 claims description 3
238000012986 modification Methods 0.000 claims description 3
206010028417 myasthenia gravis Diseases 0.000 claims description 3
208000003786 myxedema Diseases 0.000 claims description 3
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
239000002599 prostaglandin synthase inhibitor Substances 0.000 claims description 3
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 claims description 2
101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 claims description 2
101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 claims description 2
101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 claims description 2
102000043131 MHC class II family Human genes 0.000 claims description 2
108091054438 MHC class II family Proteins 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
230000000840 anti-viral effect Effects 0.000 claims description 2
229940079322 interferon Drugs 0.000 claims description 2
230000017854 proteolysis Effects 0.000 claims 1
229940024606 amino acid Drugs 0.000 description 94
201000002491 encephalomyelitis Diseases 0.000 description 71
210000001744 T-lymphocyte Anatomy 0.000 description 54
241000699670 Mus sp. Species 0.000 description 49
229920005604 random copolymer Polymers 0.000 description 42
208000024891 symptom Diseases 0.000 description 41
108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 31
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
210000004027 cell Anatomy 0.000 description 27
201000010099 disease Diseases 0.000 description 27
108090000623 proteins and genes Proteins 0.000 description 27
108700018351 Major Histocompatibility Complex Proteins 0.000 description 26
102000004169 proteins and genes Human genes 0.000 description 26
235000018102 proteins Nutrition 0.000 description 25
230000005764 inhibitory process Effects 0.000 description 21
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 21
238000011282 treatment Methods 0.000 description 19
150000001875 compounds Chemical class 0.000 description 18
239000000427 antigen Substances 0.000 description 16
238000002649 immunization Methods 0.000 description 16
108010072051 Glatiramer Acetate Proteins 0.000 description 15
108091008874 T cell receptors Proteins 0.000 description 15
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 15
108091007433 antigens Proteins 0.000 description 15
102000036639 antigens Human genes 0.000 description 15
230000000694 effects Effects 0.000 description 15
235000018977 lysine Nutrition 0.000 description 15
102000004196 processed proteins & peptides Human genes 0.000 description 15
238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 14
229940038717 copaxone Drugs 0.000 description 14
230000006698 induction Effects 0.000 description 14
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 13
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 13
210000000612 antigen-presenting cell Anatomy 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 11
230000003053 immunization Effects 0.000 description 11
239000000243 solution Substances 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
230000001712 encephalitogenic effect Effects 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
230000004044 response Effects 0.000 description 9
101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
102100038823 RNA-binding protein 45 Human genes 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
238000003556 assay Methods 0.000 description 8
210000004408 hybridoma Anatomy 0.000 description 8
239000000463 material Substances 0.000 description 8
230000035755 proliferation Effects 0.000 description 8
230000003210 demyelinating effect Effects 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
238000010532 solid phase synthesis reaction Methods 0.000 description 7
108700028369 Alleles Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000030741 antigen processing and presentation Effects 0.000 description 6
238000011161 development Methods 0.000 description 6
108010058597 HLA-DR Antigens Proteins 0.000 description 5
102000006354 HLA-DR Antigens Human genes 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
-1 N-carboxyamino acid anhydrides Chemical class 0.000 description 5
238000010171 animal model Methods 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
230000003993 interaction Effects 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
239000012071 phase Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000011347 resin Substances 0.000 description 5
229920005989 resin Polymers 0.000 description 5
238000000926 separation method Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
206010011968 Decreased immune responsiveness Diseases 0.000 description 4
206010012305 Demyelination Diseases 0.000 description 4
108010002350 Interleukin-2 Proteins 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
230000001363 autoimmune Effects 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000008030 elimination Effects 0.000 description 4
238000003379 elimination reaction Methods 0.000 description 4
238000011577 humanized mouse model Methods 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000010807 negative regulation of binding Effects 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000005067 remediation Methods 0.000 description 4
238000004007 reversed phase HPLC Methods 0.000 description 4
210000000278 spinal cord Anatomy 0.000 description 4
102000003390 tumor necrosis factor Human genes 0.000 description 4
238000002255 vaccination Methods 0.000 description 4
241001227713 Chiron Species 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
108010093013 HLA-DR1 Antigen Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
108010083674 Myelin Proteins Proteins 0.000 description 3
102000006386 Myelin Proteins Human genes 0.000 description 3
102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 3
108010010974 Proteolipids Proteins 0.000 description 3
102000016202 Proteolipids Human genes 0.000 description 3
101100273635 Rattus norvegicus Ccn5 gene Proteins 0.000 description 3
239000006180 TBST buffer Substances 0.000 description 3
108700019146 Transgenes Proteins 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
239000011616 biotin Substances 0.000 description 3
238000013461 design Methods 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000010828 elution Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229920000140 heteropolymer Polymers 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000002372 labelling Methods 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000009696 proliferative response Effects 0.000 description 3
230000008707 rearrangement Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000012384 transportation and delivery Methods 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
108700031361 Brachyury Proteins 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
101150082328 DRB5 gene Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
LOOZZTFGSTZNRX-VIFPVBQESA-N L-Homotyrosine Chemical group OC(=O)[C@@H](N)CCC1=CC=C(O)C=C1 LOOZZTFGSTZNRX-VIFPVBQESA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
101100117569 Oryza sativa subsp. japonica DRB6 gene Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
239000003875 Wang resin Substances 0.000 description 2
239000003070 absorption delaying agent Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000000981 bystander Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
239000002612 dispersion medium Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
102000054766 genetic haplotypes Human genes 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000005012 myelin Anatomy 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
210000003289 regulatory T cell Anatomy 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
KNCHTBNNSQSLRV-YFKPBYRVSA-N (2s)-6-amino-2-[(2,2,2-trifluoroacetyl)amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)C(F)(F)F KNCHTBNNSQSLRV-YFKPBYRVSA-N 0.000 description 1
SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
AYXZIZMZXAORLO-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 AYXZIZMZXAORLO-UFLZEWODSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 description 1
101001030197 Homo sapiens Myelin transcription factor 1 Proteins 0.000 description 1
101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 1
101000619805 Homo sapiens Peroxiredoxin-5, mitochondrial Proteins 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000001399 Kallikrein Human genes 0.000 description 1
108060005987 Kallikrein Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
229920001367 Merrifield resin Polymers 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101000981991 Mus musculus Myelin proteolipid protein Proteins 0.000 description 1
101001135737 Mus musculus Parathyroid hormone-related protein Proteins 0.000 description 1
101000619799 Mus musculus Peroxiredoxin-5, mitochondrial Proteins 0.000 description 1
241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
230000017274 T cell anergy Effects 0.000 description 1
230000033540 T cell apoptotic process Effects 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
108010013985 adhesion receptor Proteins 0.000 description 1
102000019997 adhesion receptor Human genes 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000006470 autoimmune attack Effects 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000010432 diamond Substances 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
239000003822 epoxy resin Substances 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000834 fixative Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000007306 functionalization reaction Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
229960003776 glatiramer acetate Drugs 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
150000004820 halides Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000050902 human MYT1 Human genes 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000007392 microtiter assay Methods 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
108010087487 myelin basic protein 85-99 Proteins 0.000 description 1
210000003007 myelin sheath Anatomy 0.000 description 1
210000000715 neuromuscular junction Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920000647 polyepoxide Polymers 0.000 description 1
208000019629 polyneuritis Diseases 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
229940124606 potential therapeutic agent Drugs 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
208000026526 progressive weakness Diseases 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000012121 regulation of immune response Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
229950003937 tolonium Drugs 0.000 description 1
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
150000003667 tyrosine derivatives Chemical class 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CA2768340A 2001-10-03 2002-10-03 Copolymeres destines a la suppression de maladies auto-immunes, et methodes d'utilisation Expired - Fee Related CA2768340C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US32670501P	2001-10-03	2001-10-03
US60/326,705		2001-10-03
CA2614171A CA2614171C (fr)	2001-10-03	2002-10-03	Copolymeres destines a la suppression de maladies auto-immunes, et methodes d'utilisation

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2614171A Division CA2614171C (fr)	2001-10-03	2002-10-03	Copolymeres destines a la suppression de maladies auto-immunes, et methodes d'utilisation

Publications (2)

Publication Number	Publication Date
CA2768340A1 true CA2768340A1 (fr)	2003-04-10
CA2768340C CA2768340C (fr)	2015-06-30

Family

ID=45809709

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2768340A Expired - Fee Related CA2768340C (fr)	2001-10-03	2002-10-03	Copolymeres destines a la suppression de maladies auto-immunes, et methodes d'utilisation

Country Status (1)

Country	Link
CA (1)	CA2768340C (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113473996A (zh) *	2019-03-05	2021-10-01	陶氏环球技术有限责任公司	诱导胱天蛋白酶活性
WO2022103673A2 (fr)	2020-11-10	2022-05-19	Fridkis Hareli Masha	Compositions de peptides aléatoires d'épitope incorporés (eerp) pour le traitement d'états à médiation immunitaire, et procédés d'utilisation

2002
- 2002-10-03 CA CA2768340A patent/CA2768340C/fr not_active Expired - Fee Related

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113473996A (zh) *	2019-03-05	2021-10-01	陶氏环球技术有限责任公司	诱导胱天蛋白酶活性
CN113473996B (zh) *	2019-03-05	2024-05-24	陶氏环球技术有限责任公司	诱导胱天蛋白酶活性
US12251399B2 (en)	2019-03-05	2025-03-18	Dow Global Technologies Llc	Inducing caspase activity
WO2022103673A2 (fr)	2020-11-10	2022-05-19	Fridkis Hareli Masha	Compositions de peptides aléatoires d'épitope incorporés (eerp) pour le traitement d'états à médiation immunitaire, et procédés d'utilisation

Also Published As

Publication number	Publication date
CA2768340C (fr)	2015-06-30

Legal Events

Date	Code	Title	Description
2012-02-09	EEER	Examination request
2018-11-14	MKLA	Lapsed	Effective date: 20181003

Publication	Publication Date	Title
US8017125B2 (en)	2011-09-13	Copolymers for suppression of autoimmune diseases, and methods of use
AU2002362445A1 (en)	2003-06-26	Copolymers for suppression of autoimmune diseases, and methods of use
JP5892815B2 (ja)	2016-03-23	ランダム共重合体を用いる疾患の治療方法
US20100316714A1 (en)	2010-12-16	Methods of treating disease with random copolymers
US7456252B2 (en)	2008-11-25	Therapeutic peptides for demyelinating conditions
CA2614171C (fr)	2012-04-24	Copolymeres destines a la suppression de maladies auto-immunes, et methodes d'utilisation
CA2768340C (fr)	2015-06-30	Copolymeres destines a la suppression de maladies auto-immunes, et methodes d'utilisation
US20070264229A1 (en)	2007-11-15	Peptides for Treatment of Autoimmune Disease